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Experimental 
 
General Experimental 
 
Chemicals, solvents and reagents used are commercially available and were used without 
further purification. PE refers to petroleum ether, bp 40-60 °C. TLCs were carried out on 
Merck Aluminium backed TLC plates Silica Gel 60 F254 and viewed using UV light of 
wavelength 254 nm and then stained with potassium permanganate. Merck Silica Gel 
(0.040-0.063 mm) was used for column chromatography. Compounds were loaded as an 
oil, CH2Cl2 solution or dry loaded by adsorption onto silica.  
 
Melting points were obtained using a Reichert-Jung heated-stage microscope. Infrared 
spectra were recorded on a Perkin-Elmer Spectrum RXI FT-IR system and all values are 
recorded in cm−1. 
 
NMR spectra were obtained on Varian Mercury VX (400 MHz) or Bruker Avance III 
(400 MHz) spectrometers. The chemical shifts are recorded in parts per million (ppm) 
with reference to tetramethylsilane. The coupling constants J are quoted to the nearest 0.5 
Hz and are not corrected. The multiplicities are assigned as a singlet (s), doublet (d), 
triplet (t), doublet of doublets (dd) and multiplet (m). Mass spectra and high resolution 
mass spectra were obtained on a micrOTOFTM from Bruker Daltonics (Bremen, Germany) 
coupled with an electrospray source (ESI-TOF) using an autosampler in an Agilent 1100 
LC system. Data was processed using external calibration with the Bruker Daltonics 
software, DataAnalysisTM as part of the overall hardware control software, Compass 
1.1TM. 
 
 
HPLC 
 
Analytical RP-HPLC was performed on a Dionex HPLC system equipped with a Dionex 
Acclaim 3 µm C-18 (150 × 4.6 mm) column with a flow rate of 1 mL/min. with detection 
at 214 nm and 254 nm shown (pages S30-S41). Mobile phase A was 0.1% TFA in H2O 
and mobile phase B was 0.1% TFA in MeCN. The gradient was T = 0 min., B = 5%; T = 
10 min., B = 95%; T = 15 min., B = 95%; T = 15.1 min., B = 5%; T = 18.1 min., B = 5%. 
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MTS cell proliferation assay1 
1: Human cancer cell lines HT29, MDA-MB-231 and LNCaP were supplied by Cancer 
Research UK. They were maintained in DMEM with high glucose (4.5 g/L) and L-
glutamine, supplemented with penicillin 100 U/mL, streptomycin 100 µg/mL and 
foetal bovine serum at 10% for HT29 and MDA-MB-231, and 20% for LNCaP. FEK-
4 primary human skin fibroblasts were a gift from Prof. Rex M. Tyrrell (University of 
Bath) and were maintained in MEM supplemented with L-glutamine, supplemented 
with penicillin 100 U/mL, streptomycin 100 µg/mL and 15% foetal bovine serum. All 
reagents supplied by Invitrogen. 
Cells were maintained in 75 cm2 tissue culture flasks (Nunc) with a weekly 1:10 split. 
 
2: For the MTS assay, seed densities of 500, 1000, 1500 and 2000 cells per well in 50 
µL were used for HT29, MDA-MB-231, FEK-4 and LNCaP cell lines respectively. 
 The seed densities had been determined previously to give an acceptable optical 
density value after 3 days incubation. 
 
3: Plates were incubated at 37 oC, in humidified 5% CO2 in air for 2-4 hours. 
 
4: Test agents were prepared at 100 × final concentration in DMSO (Sigma), diluted 1 in 
50 in culture medium and 50 µl added to the appropriate wells, to give a final volume 
of 100 µl. 
 
5: Quadruplicate samples were run as follows: 
 
 Culture medium only (background) 
 Cells only 
 Cells + 1% DMSO 
 Cells + test compound 
 
6: Plates were incubated at 37 oC, in humidified 5% CO2 in air for 3 days. 
 This exposure time appears to be adequate to demonstrate anti-proliferative activity, 
and is routinely used by other workers. 
 
7: The MTS reagent was added, 20 µl per well. 
 This is Promega Cell Titer® Aqueous One Solution Cell Proliferation Assay. 
 
8: Plates were incubated at 37 oC, in humidified 5% CO2 in air, for colour development. 
 
9: Optical density readings at 490nm were taken at 1-4 hours. 
 
10: Because the culture medium gives a high OD490nm this was subtracted from all other 
OD490nm values prior to calculation of mean and s.d. 
 
11: Means and standard deviations were calculated from background corrected OD490nm 
values. 
 
12: IC50 values were calculated using the pharmacology function in SigmaPlot 8 (SPSS 
Inc). Each assay was repeated on three separate occasions, except A3 FEK-4 (twice) 
and C3-H2 FEK-4 and Doxorubicin (once), and average IC50 values with standard 
deviations determined. Doxorubicin was used as a positive control. 
 
Note: This assay is based upon the development of a coloured metabolite from viable cells. 
Therefore the inhibition of colour development by an active agent does not distinguish 
between inhibition of cell metabolism ie cytostasis and reduction in cell number ie 
cytotoxicity. Nevertheless, this assay provides a very quick and easy first approach for 
screening test compounds. 
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General Methods 
 
Method i (A1, B1, C1) 
 
 
 
Following the procedure reported,2 except using 1 equivalent LiOH.H2O, LiOH.H2O (2.5 
mmol) was added to rapidly stirred solution of acetophenone (2.5 mmol) in EtOH (2 mL) 
at 30 oC open to the atmosphere for 10 min. resulting in a rapid colour change from 
colourless to yellow. The aldehyde (2.5 mmol) was then added and stirring continued for 
6 h resulting in a gradual colour change from yellow to orange. After 6 h the solvent was 
removed under reduced pressure and distilled water (5 mL) added followed by 1.5M 
HCl(aq) (5 mL) to the remaining residue. The product was extracted with EtOAc (3 × 20 
mL), the organic layers were combined and washed with saturated brine solution (20 mL). 
The organic fraction was dried (Na2SO4), filtered and solvent removed under reduced 
pressure to give a yellow solid. The solid was purified by column chromatography with 
silica gel using PE:EtOAc 6:4 to afford the desired chalcone. 
 
 
(E)-1-(4-methoxyphenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one (A1) 
 
Following Method i on a 5 mmol scale, the product A1 was obtained as a yellow solid 
(0.49 g, 43%). 
Mp 170-172 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3050, 1649 and 1594; 
1H NMR δH(400 MHz; CDCl3) 3.87 (3 H, s, OCH3), 6.31-6.33 (1 H, m, pyrrole CH), 
6.65-6.70 (1 H, m, pyrrole CH), 6.95 (2 H, d, J 9.0 Hz, Ar CH), 6.94-6.96 (1 H, m, 
pyrrole CH), 7.16 (1 H, d, J 15.0 Hz, COCH=CH), 7.73 (1 H, d, J 15.0 Hz, COCH=CH), 
7.99 (2 H, d, J 8.5 Hz, Ar CH) and 8.95 (1 H, br s, pyrrole NH); 
13C NMR δc(100MHz; CDCl3) 55.46 (OCH3), 111.4 (pyrrole CH), 113.8 (pyrrole CH), 
114.7 (Ar CH), 115.7 (pyrrole CH), 122.3 (Ar CH), 129.5 (Cq), 130.5 (HC=CH), 131.6 
(Cq), 133.8 (HC=CH), 163.2 (Cq) and 188.7 (C=O); 
MS m/z (ES+) Found 228.1025 (MH+) and 250.0846 (MNa+). C14H14NO2 (MH+) requires 
228.1025 and C14H13NO2Na (MNa+) requires 250.0844. 
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(E)-1-(3,4-dimethoxyphenyl)-3-(1H-pyrrol-2-yl)prop-2-en-1-one (B1) 
 
Following Method i, the product B1 was obtained as a yellow solid (0.34 g, 53%). 
Mp 80-81 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3458, 1651 and 1584; 
1H NMR δH(400 MHz; CDCl3) 3.91 (3 H, s, OCH3), 3.92 (3 H, s, OCH3), 6.31-6.33 (1 H, 
m, pyrrole CH), 6.69-6.71 (1 H, m, pyrrole CH), 6.85 (1 H, d, J 8.0, Ar CH), 6.95-6.98 (1 
H, m, pyrrole CH), 7.21 (1 H, d, J 15.5 Hz, COCH=CH), 7.59 (1 H, d, J 1.5 Hz, Ar CH), 
7.61 (1 H, dd, J 1.5 and 8.5 Hz, Ar CH), 7.75 (1 H, d, J 15.5 Hz, COCH=CH) and 9.25 (1 
H, br s, pyrrole NH); 
13C NMR δc(100MHz; CDCl3) 56.0 (OCH3), 110.1 (pyrrole CH), 111.0 (pyrrole CH), 
111.4 (pyrrole CH), 115.0 (Ar CH), 115.4 (Ar CH), 122.6 (Ar CH), 122.9 (HC=CH), 
129.5 (Cq), 131.8 (Cq), 134.0 (HC=CH), 149.2 (Cq), 153.0 (Cq) and 188.7 (C=O); 
MS m/z (ES+) Found 258.1135 (MH+) and 280.0949 (MNa+). C15H16NO3 (MH+) requires 
258.1130 and C15H15NO3Na (MNa+) requires 280.0950. 
 
 
 
 
(E)-3-(1H-pyrrol-2-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C1) 
 
Following Method i, the product C1 was obtained as a yellow solid (0.53 g, 74%). 
Mp 104-106 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3457, 1654 and 1575; 
1H NMR δH(400 MHz; DMSO) 3.76 (3 H, s, OCH3), 3.90 (6 H, s, OCH3), 6.22-6.24 (1 H, 
m, pyrrole CH), 6.74-6.75 (1 H, m, pyrrole CH), 7.15-7.16 (1 H, m, pyrrole CH), 7.35 (2 
H, s, Ar CH), 7.54 (1 H, d, J 15.0 Hz, COCH=CH), 7.62 (1 H, d, J 15.0 Hz, COCH=CH) 
and 11.71 (1 H, br s, pyrrole NH); 
13C NMR δc(100MHz; DMSO) 56.1 (OCH3), 60.2 (OCH3), 105.7 (Ar CH), 110.6 (pyrrole 
CH), 114.4 (pyrrole CH), 116.4 (pyrrole CH), 124.1 (HC=CH) 129.2 (Cq), 133.7 (Cq), 
134.1 (HC=CH), 141.5 (Cq), 152.9 (Cq) and 187.1 (C=O); 
MS m/z (ES+) Found 288.1241 (MH+) and 310.1061 (MNa+). C16H18NO4 (MH+) requires 
288.1236 and C16H17NO4Na (MNa+) requires 310.1055. 
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Method ii (A2, B2, C2) 
 
 
Following the procedure reported,3 acetophenone (5 mmol), the aldehyde (5 mmol) and 
NaOH (7 mmol) was added to a porcelain mortar and ground using a porcelain pestle at 
room temperature (20 oC) for 5 min. resulting in the formation of a viscous yellow paste. 
The paste was then purified by column chromatography with silica gel using PE:EtOAc 
6:4 solvent system to afford the desired chalcone. 
 
 
(E)-1-(4-methoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (A2) 
 
Following Method ii, the product A2 was obtained as a yellow solid (0.76 g, 63%). 
Mp 101-103 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 1654 and 1575; 
1H NMR δH(400 MHz; CDCl3) 3.74 (3 H, s, pyrrole CH3), 3.87 (OCH3), 6.20-6.22 (1 H, 
m, pyrrole CH), 6.79-6.80 (1 H, m, pyrrole CH), 6.82-6.83 (1 H, m, pyrrole CH), 6.96 (2 
H, d, J 9.0 Hz, Ar CH), 7.31 (1 H, d, J 15.0 Hz, COCH=CH), 7.79 (1 H, d, J 15.0 Hz, 
COCH=CH) and 8.02 (2 H, d, J 9.0 Hz, Ar CH); 
13C NMR δc(100MHz; CDCl3) 34.3 (pyrrole CH3), 55.4 (OCH3), 109.5 (pyrrole CH), 
111.9 (pyrrole CH), 113.7 (Ar CH), 116.5 (pyrrole CH), 127.4 (HC=CH), 130.3 (Cq), 
130.4 (Ar CH), 131.4 (HC=CH), 131.5 (Cq), 163.0 (Cq) and 188.2 (C=O); 
MS m/z (ES+) Found 242.1191 (MH+) and 264.1007 (MNa+). C15H16NO2 (MH+) requires 
242.1181 and C15H15NO2Na (MNa+) requires 264.1001. 
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(E)-1-(3,4-dimethoxyphenyl)-3-(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (B2) 
O O
H
ONaOH
grinding
N N
MeO MeO
B2
MeO MeO
2-CHO
Me Me
B  
Following Method ii, the product B2 was obtained as a yellow solid (1.07 g, 79%). 
Mp 126-126 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 1647, 1597 and 1573; 
1H NMR δH(400 MHz; CDCl3) 3.75 (3 H, s, pyrrole CH3), 3.94 (3 H, s, OCH3), 3.95 (3 H, 
s, OCH3), 6.19-6.21 (1 H, m, pyrrole CH), 6.78-6.79 (1 H, m, pyrrole CH), 6.82-6.83 (1 
H, m, pyrrole CH), 6.90 (1 H, d, J 8.5 Hz, Ar CH), 7.30 (1 H, d, J 15.5 Hz, COCH=CH), 
7.61 (1 H, d, J 2.0 Hz, Ar CH), 7.64 (1 H, dd, J 2.0 and 8.0 Hz, Ar CH) and 7.79 (1 H, d, 
J 15.0 Hz, COCH=CH); 
13C NMR δc(100MHz; CDCl3) 34.3 (pyrrole CH3), 55.9 (OCH3), 56.0 (OCH3), 109.6 
(pyrrole CH), 109.9 (pyrrole CH), 110.6 (pyrrole CH), 111.9 (Ar CH), 116.3 (Ar CH), 
122.4 (HC=CH), 127.5 (Ar CH) 130.3 (HC=CH), 131.4 (Cq), 131.7 (Cq), 149.0 (Cq), 
152.8 (Cq) and 188.0 (C=O); 
MS m/z (ES+) Found 272.1273 (MH+) and 294.1094 (MNa+). C16H18NO3 (MH+) requires 
272.1287 and C16H17NO3Na (MNa+) requires 294.1106. 
 
 
 
(E)-3-(1-methyl-1H-pyrrol-2-yl)-(3,4,5-trimethoxyphenyl)prop-2-one (C2) 
 
Following Method ii, the product C2 was obtained as an orange oil (1.25 g, 83%). 
IR νmax(film)/cm-1 1647 and 1568; 
1H NMR δH(400 MHz; CDCl3) 3.77 (3 H, s, pyrrole CH3), 3.92 (3 H, s, OCH3), 3.94 (6 H, 
s, OCH3), 6.21-6.24 (1 H, m, pyrrole CH), 6.81-6.83 (1 H, m, pyrrole CH), 6.85-6.87 (1 
H, m, pyrrole CH), 7.21 (1 H, d, J 15.0 Hz, COCH=CH), 7.26 (2 H, s, Ar CH) and 7.80 (1 
H, d, J 15.0 Hz, COCH=CH); 
13C NMR δc(100MHz; CDCl3) 34.3 (pyrrole CH3), 56.3 (OCH3), 56.3 (OCH3), 105.7 (Ar 
CH), 109.7 (pyrrole CH), 112.2 (pyrrole CH), 116.4 (pyrrole CH), 127.8 (HC=CH), 130.2 
(Cq), 132.1 (HC=CH), 134.1 (Cq), 153.0 (Cq), 153.0 (Cq) and 188.7 (C=O); 
MS m/z (ES+) Found 302.1371 (MH+) and 324.1192 (MNa+). C17H20NO4 (MH+) requires 
302.1392 and C17H19NO4Na (MNa+) requires 324.1212. 
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Method iii (A3, B3, C3) 
 
 
 
Following the procedure reported,4 except using 2 equivalents of BF3·OEt2, BF3·OEt2 (5 
mmol) was added dropwise under dry conditions to a rapidly stirred solution of 
acetophenone (2.5 mmol) and aldehyde (2.5 mmol) in dry dioxane (2 mL) under N2 at 25 
oC. The solution was heated to 75 oC for 6 h and the reaction followed by TLC. The 
reaction was cooled and quenched by addition of EtOAc (100 mL) and distilled water 
(100 mL) and the aqueous fractions extracted with EtOAc (3 × 50 mL). 2M NaOH (50 
mL) was added to the aqueous layer and gently heated at 50 oC with magnetic stirring for 
30 min., resulting in a slight colour change and formation of a black precipitate. The 
aqueous layer was extracted with EtOAc (3 × 50 mL) and the organic layers were 
combined and washed with saturated brine solution (50 mL) and dried using Na2SO4. The 
solvent was filtered and removed under reduced pressure to produce a yellow/orange 
solid/oil which was purified by column chromatography with silica gel using 
CH2Cl2:MeOH 9:1 solvent system to afford the desired chalcone. 
 
 
 
(E)-3-(1H-imidazol-5-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (A3) 
O O
H
O2 equiv. BF3.OEt2
HN
N
HN
N
MeO MeO
A33-CHOA  
Following Method iii, the product A3 was obtained as an orange solid (0.30 g, 53%). 
Mp 173-175 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3458, 1660 and 1604; 
1H NMR δH(400 MHz; DMSO) 3.85 (3 H, s, OCH3), 7.08 (2 H, d, J 9.0 Hz, Ar CH), 7.63 
(1 H, d, J 15.0 Hz, COCH=CH), 7.67 (1 H, d, J 15.5 Hz, COCH=CH), 7.64 (1 H, s, Im 
CH), 7.85 (1 H, s, Im CH), 8.03 (2 H, d, J 9.0 Hz, Ar CH) and 12.56 (1 H, br s, Im NH); 
13C NMR δc(100MHz; DMSO) 55.5 (OCH3), 114.0, 117.8, 130.4 (Ar CH, Im CH and 
HC=CH), 130.8 (Cq), 162.8 (Cq), 162.9 (Cq) and 187.2 (C=O); 
MS m/z (ES+) Found 229.0978 (MH+). C13H13N2O2 (MH+) requires 229.0977. 
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(E)-1-(3,4-dimethoxyphenyl)-3-(1H-imidazol-5-yl)prop-2-en-1-one (B3) 
O O
H
O2 equiv. BF3.OEt2
HN
N
HN
N
MeO MeO
B3
MeO MeO
3-CHOB  
Following Method iii, the product B3 was obtained as a pale yellow solid (0.48 g, 74%). 
Mp 170-171 oC (THF/heptane); 
IR νmax(film)/cm-1 3457, 1659 and 1605; 
1H NMR δH(400 MHz; DMSO) 3.85 (3 H, s, OCH3), 3.86 (3 H, s, OCH3), 7.10 (1 H, d, J 
8.5 Hz, Ar CH), 7.54 (1 H, d, J 2.0 Hz, Ar CH), 7.64 (1 H, d, J 15.0 Hz, COCH=CH), 
7.64 (1 H, s, Im CH), 7.68 (1 H, d, J 15.5 Hz, COCH=CH), 7.73 (1 H, dd, J 2.0 and 8.5 
Hz, Ar CH), 7.86 (1 H, s, Im CH) and 12.30 (1 H, br s, Im NH); 
13C NMR δc(100MHz; DMSO) 55.5 (OCH3), 55.7 (OCH3), 110.5 (Ar CH), 110.9 (Ar 
CH), 117.7 (Im CH), 122.6 (Ar CH), 130.9 (Cq), 135.0 (HC=CH) 135.6 (HC=CH). 138.0 
(Im CH) 148.8 (Cq), 152.9 (Cq) and 187.2 (C=O); 
MS m/z (ES+) Found 259.1082 (MH+) and 281.0897 (MNa+). C14H15N2O3 (MH+) requires 
259.1083 and C14H14N2O3Na (MNa+) requires 281.0902. 
 
 
 
 
 
(E)-3-(1H-imidazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C3) 
 
Following Method iii, the product C3 was obtained as an orange solid (0.53 g, 74%). 
Mp 174-176 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3456, 1661 and 1581; 
1H NMR δH(400 MHz; CDCl3) 3.85 (6 H, s, OCH3), 3.89 (3 H, s, OCH3), 7.26 (2 H, Ar 
CH), 7.38 (1 H, s, Im CH), 7.69 (1 H, d, J 15.5 Hz, COCH=CH), 7.77 (1 H, s, Im CH), 
7.77 (1 H, d, J 15.0 Hz, COCH=CH) and 8.17 (1 H, br s, Im NH); 
13C NMR δc(100MHz; CDCl3) 56.2 (OCH3), 60.9 (OCH3), 105.9 (Ar CH), 119.3 (Im 
CH), 123.4 (Im CH), 133.4 (Cq), 134.6 (HC=CH), 135.9 (Cq), 137.2 (HC=CH), 142.3 
(Cq), 153.0 (Cq) and 189.1 (C=O); 
MS m/z (ES+) Found 289.1183 (MH+). C15H17N2O4 (MH+) requires 289.1188. 
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(E)-3-(1-methyl-1H-imidazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C4) 
O O
H
O2 equiv. BF3.OEt2
N
N
N
N
MeO MeO
C4
MeO MeO
OMe OMe4-CHO
Me Me
C  
Following Method iii, the product C4 was obtained as an orange oil (0.41 g, 54%). 
IR νmax(film)/cm-1 1657, 1591 and 1579; 
1H NMR δH(400 MHz; CDCl3) 3.78 (3 H, s, Im CH3), 3.94 (3 H, s, OCH3), 3.95 (6 H, s, 
OCH3), 7.25 (2 H, s, Ar CH), 7.37 (1 H, d, J 15.5 Hz, COCH=CH), 7.57 (1 H, s, Im CH), 
7.65 (1 H, s, Im CH) and 7.69 (1 H, d, J 15.0 Hz, COCH=CH); 
13C NMR δc(100 MHz; CDCl3) 32.1 (Im CH3), 56.4 (OCH3), 61.0 (OCH3), 105.9 (Ar 
CH), 119.6 (Im CH), 129.1 (Im CH), 129.6 (Cq), 132.3 (HC=CH), 133.3 (Cq), 141.1 
(HC=CH), 142.6 (Cq), 153.1 (Cq) and 188.2 (C=O); 
MS m/z (ES+) Found 303.1337 (MH+) and 325.1150 (MNa+). C16H19N2O4 (MH+) requires 
303.1345 and C16H18N2O4Na (MNa+) requires 325.1164. 
 
 
 
 
(E)-3-(1H-imidazol-2-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C6) 
 
Following Method iii on a 5 mmol scale, the product C6 was obtained as a yellow solid 
(0.55 g, 38%). 
Mp 198-201 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 3439, 1661, 1607 and 1582; 
1H NMR δH(400 MHz; CDCl3) 3.89 (6 H, s, OCH3), 3.93 (3 H, s, OCH3), 7.26-7.30 (4 H, 
m, Ar CH and Im CH), 7.75 (1 H, d, J 15.0 Hz, COCH=CH) and 7.86 (1 H, d, J 15.0 Hz, 
COCH=CH); 
13C NMR δc(100MHz; CDCl3) 56.3 (OCH3), 61.0 (OCH3), 106.1 (Ar CH and Im CH), 
122.4 (HC=CH), 131.0 (HC=CH), 132.8 (Cq), 142.8 (Cq), 143.8 (Cq), 153.2 (Cq) and 
188.7 (C=O); 
MS m/z (ES+) Found 289.1184 (MH+) and 311.0998 (MNa+). C15H17N2O4 (MH+) requires 
289.1188 and C15H16N2O4Na (MNa+) requires 311.1008. 
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Method iv (C3-H2) 
3-(1H-imidazol-5-yl)-(3,4,5-trimethoxyphenyl)propan-1-one (C3-H2) 
 
The chalcone C3 (100 mg, 0.347 mmol) was added to a stirred solution of 10wt% Pd/C 
(20 mg) in MeOH (4 mL) under 1 atm of H2 and stirring continued at 25 oC for 19 h. The 
reaction was then quenched with EtOAc (50 mL) and washed through celite with distilled 
water, the organic layer was extracted with EtOAc (3 × 50 mL) and the organic layers 
were combined and washed with saturated brine solution (50 mL). The organic fraction 
was dried (Na2SO4), filtered and solvent removed under reduced pressure to give the 
product C3-H2 as a pale yellow oil (0.057 g, 57%) without the need for further 
purification. 
IR νmax(film)/cm-1 3454, 1678, 1586 and 1505; 
1H NMR δH(400 MHz; CDCl3) 3.05 (2 H, t, J 7.0 Hz, CH2), 3.35 (2 H, t, J 7.0 Hz, CH2), 
3.89 (6 H, s, OCH3), 3.90 (3 H, s, OCH3), 6.85 (1 H, s, Im CH), 7.21 (2 H, s, Ar CH), 
7.45 (1 H, br s, Im NH) and 7.65 (1 H, s, Im CH); 
13C NMR δc(100MHz; CDCl3) 20.5 (CH2), 38.2 (CH2), 56.3 (OCH3), 60.9 (OCH3), 105.5 
(Ar CH), 118.2 (Im CH), 131.9 (Cq), 134.2 (Im CH), 135.1 (Cq), 142.7 (Cq), 153.0 (Cq) 
and 198.7 (C=O); 
MS m/z (ES+) Found 291.1350 (MH+) and 313.1162 (MNa+). C15H19N2O4 (MH+) requires 
291.1345 and (MNa+) C15H18N2O4Na requires 313.1164. 
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Method v (C5) 
(E)-3-(1-methyl-1H-imidazol-4-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C5) 
 
 
Following the procedure reported,5 except cooled to 0 oC, NaH (60% dispersion in 
mineral oil, 1.5 mmol) was added to a stirred solution of the chalcone (1.0 mmol) in DMF 
(5 mL) at 0 oC followed by dropwise addition of MeI (1.5 mmol) and the reaction was 
kept at 0 oC and followed by TLC until the disappearance of the chalcone starting 
material. The reaction was quenched with the addition of EtOAc (50 mL) and H2O (50 
mL), the organic layer separated and the aqueous fraction extracted with EtOAc (2 × 50 
mL). The organic fractions were combined and washed with saturated brine solution (20 
mL). The organic fraction was dried (Na2SO4), filtered and solvent removed under 
reduced pressure. Crude 1H NMR revealed the presence of C4, in addition to the product 
C5 in a ratio of 25:75 (C4:C5). The mixture was purified by column chromatography 
with silica gel using CH2Cl2:IPA solvent system increasing from 0% to 12% IPA in 1% 
increments of 200 mL to afford the desired product C5 as an orange oil (0.11g, 36%). 
Rf (12% IPA in CH2Cl2) = 0.63 (C5), 0.47 (C4); 
IR νmax(film)/cm-1 1659, 1603 and 1580; 
1H NMR δH(400 MHz; CDCl3) 3.71 (3 H, s, Im CH3), 3.90 (3 H, s, OCH3), 3.92 (6 H, s, 
OCH3), 7.15 (1 H, s, Im CH), 7.33 (2 H, s, Ar CH), 7.49 (1 H, s, Im CH) and 7.70 (2 H, s, 
COCH=CH); NB The peak at δH 7.70 ppm can vary depending on the concentarion of the 
sample and can appear as two doublets; 
1H NMR – Diluted δH(400 MHz; CDCl3) 3.73 (3 H, s, Im CH3), 3.92 (3 H, s, OCH3), 
3.94 (6 H, s, OCH3), 7.17 (1 H, s, Im CH), 7.34 (2 H, s, Ar CH), 7.50 (1 H, s, Im CH), 
7.69 (1 H, d, J 15.0 Hz, COCH=CH) and 7.74 (1 H, d, J 15.0 Hz, COCH=CH); 
13C NMR δc(100MHz; CDCl3) 33.8 (Im CH3), 56.4 (OCH3), 60.9 (OCH3), 106.0 (Ar CH), 
119.6 (Im CH) 124.1 (Im CH), 133.6 (Cq), 135.1 (HC=CH), 138.0 (Cq), 139.1 (HC=CH), 
142.3 (Cq), 153.1 (Cq) and 188.9 (C=O); 
MS m/z (ES+) Found 303.1354 (MH+) and 325.1166 (MNa+). C16H19N2O4 (MH+) requires 
303.1345 and C16H18N2O4Na (MNa+) requires 325.1164. 
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Method vi (C7) 
(E)-3-(1-methyl-1H-imidazol-2-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (C7) 
 
The chalcone (1.4 mmol) was added to a rapidly stirred solution of 3 equivalents of 
Cs2CO3 (4.2 mmol) in THF (30 mL) at 30 oC open to the atmosphere for 15 min. followed 
by dropwise addition of 3 equivalents of MeI (4.2 mmol) and stirring continued for 6 h. 
The reaction was then cooled and quenched by addition of CH2Cl2 (50 mL) and distilled 
water (50 mL) and the organic layer extracted with CH2Cl2 (3 × 50 mL), the organic 
layers were combined and washed with saturated brine solution (50 mL). The organic 
fraction was dried (Na2SO4), filtered and solvent removed under reduced pressure to give 
a pale yellow oil. The oil was purified by column chromatography with silica using 
CH2Cl2:MeOH 9:1 solvent system to afford the product C7 as a yellow solid (0.23 g, 
54%). 
Mp 100-102 oC (EtOAc/heptane); 
IR νmax(film)/cm-1 1658, 1605 and 1580; 
1H NMR δH(400 MHz; CDCl3) 3.81 (3 H, s, Im CH3), 3.93 (3 H, s, OCH3), 3.94 (6 H, s, 
OCH3), 7.03 (1 H, s, Im CH), 7.21 (1 H, s, Im CH), 7.36 (2 H, s, Ar CH), 7.68 (1 H, d, J 
15.0 Hz, COCH=CH) and 8.06 (1 H, d, J 15.0 Hz, COCH=CH); 
13C NMR δc(100MHz; CDCl3) 33.0 (Im CH3), 56.4 (OCH3), 60.9 (OCH3), 106.0 (Ar CH), 
123.9 (HC=CH), 127.2 (Im CH), 130.3 (HC=CH), 131.4 (Im CH), 133.0 (Cq), 142.7 
(Cq), 143.7 (Cq), 153.2 (Cq) and 188.1 (C=O); 
MS m/z (ES+) Found 303.1360 (MH+) and 325.1172 (MNa+). C16H19N2O4 (MH+) requires 
303.1345 and C16H18N2O4Na (MNa+) requires 325.1164. 
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HPLC traces at 214 nm 
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HPLC traces at 254 nm 
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